Add to a list

Inactive Instrument

Mateon Therapeutics Inc Stock Nasdaq

US57667K1097

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Mateon Therapeutics Inc

Market Cap	15.96M 14.02M 13.04M 11.96M 22.48M 1.54B 22.82M 155M 60.48M 756M 59.91M 58.62M 2.61B	P/E 2024	-3.13x	P/E 2025	0.13x
Enterprise Value	29.78M 26.16M 24.33M 22.32M 41.94M 2.87B 42.59M 289M 113M 1.41B 112M 109M 4.88B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	55.11%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Mateon Therapeutics Inc

07-22	Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding	CI
07-09	Oncotelic Therapeutics, Inc. announced that it expects to receive $0.71184 million in funding	CI
07-07	Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites	CI
06-29	Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003	CI
06-22	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
06-18	Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026	CI
06-17	Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services	CI
06-17	TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility	CI
06-08	Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development	CI
05-14	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus	CI
04-30	Oncotelic Therapeutics Advances Toward Commercial Launch of Ai-Enabled Robotics Platform	CI
04-15	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

More news

Press Releases: Mateon Therapeutics Inc

07-23	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle Technology Supporting the Ongoing Clinical Development of Sapu003	AQ
07-22	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)	AQ
07-07	Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway	AQ
06-29	Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003	AQ
06-18	Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026	AQ

More press releases

Managers and Directors: Mateon Therapeutics Inc

Manager	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	61	2019-04-21
Amit Bhupendra Shah DFI	Director of Finance/CFO	59	2019-06-30
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	77	2020-01-05

Director	Title	Age	Since
Vuong Trieu CHM	Chairman	61	2019-04-21
Steven King BRD	Director/Board Member	61	2020-05-10
Anthony Maida BRD	Director/Board Member	61	2020-05-10

More insiders

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâ€™s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATEON THERAPEUTICS INC	-16.67%	-32.89%	-	-	15.96M
ARGENX SE	+0.93%	+6.97%	+59.60%	+68.35%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+83.42%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+428.78%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.53%	-16.40%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+24.13%	-6.24%	20.46B
GENMAB A/S	-1.34%	+0.51%	+26.03%	-29.41%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+38.77%	+504.71%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+291.37%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+180.07%	13.92B
Average	-2.60%	+1.28%	+40.19%	+167.18%	26.68B
Weighted average by Cap.	-0.87%	+2.10%	+39.70%	+133.49%

	2024	2025
Net sales	-	-
Net income	-4.52M -3.97M -3.7M -3.39M -6.37M -436M -6.47M -43.88M -17.14M -214M -16.98M -16.62M -741M	249M 219M 204M 187M 351M 24.01B 356M 2.42B 945M 11.8B 936M 916M 40.81B
Net Debt	13M 11.42M 10.62M 9.75M 18.31M 1.25B 18.59M 126M 49.27M 616M 48.81M 47.76M 2.13B	13.82M 12.14M 11.29M 10.36M 19.47M 1.33B 19.77M 134M 52.38M 654M 51.89M 50.78M 2.26B

Mateon Therapeutics Inc Stock Nasdaq

Stocks

US57667K1097

Biotechnology & Medical Research

Valuation: Mateon Therapeutics Inc

Latest news : Mateon Therapeutics Inc

Press Releases: Mateon Therapeutics Inc

Quotes and Performance

Managers and Directors: Mateon Therapeutics Inc

Bio Therapeutic Drugs

Financials

Company Profile